艾滋病毒阳性耐火伯基特淋巴瘤中对glofitamab的持久反应:病例报告和讨论

Bozzotto Elisa1, Magnes Theresa1, Kiem Dominik1

  • 1Department of Internal Medicine III With Hematology, Medical Oncology, Hemostaseology, Infectiology, and Rheumatology Paracelsus Medical University University Clinic Salzburg Salzburg Austria.

EJHaem
|February 16, 2026
PubMed
概括

格洛菲他马布对耐火性伯基特淋巴瘤 (BL) 患者显示有前途,这些患者已经耗尽了标准治疗方法. 仅有一名患者实现了完全缓解,在glofitamab治疗后持续了9个月.